Protocol Ledger

NCT06497127 · Phase II · ACTIVE NOT RECRUITING

A Study in Patients With Mixed Dyslipidemia

Interventional Phase II clinical trial protocol NCT06497127 sponsored by Shanghai Argo Biopharmaceutical Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-28 Enrollment: 145 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06497127
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)145 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06497127
Protocol FieldVerified Registry Value
NCT IdentifierNCT06497127
Consolidated Lead SponsorShanghai Argo Biopharmaceutical Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment145 participants (ACTUAL)
Registered Start Date2024-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06497127
Hospital Research SiteLocationSite Profile
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI